OA13136A - Pulmonary administration of chemically modified insulin. - Google Patents

Pulmonary administration of chemically modified insulin. Download PDF

Info

Publication number: OA13136A
Authority: OA; OAPI
Prior art keywords: insulin; composition; peg; polyethylene glycol; administration
Prior art date: 2001-05-21

Application number

OA1200300305A

Other languages

English (en)

French (fr)

Inventor

John S Patton

Mei-Chang Kuo

Milton J Harris

Chester Leach

Kimbery Perkins

Blaine Bueche

Original Assignee

Nektar Therapeutics

Nektar Therapeutics Al Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-21

Filing date

2002-05-21

Publication date

2006-12-13

2002-05-21 Application filed by Nektar Therapeutics, Nektar Therapeutics Al Corp filed Critical Nektar Therapeutics

2006-12-13 Publication of OA13136A publication Critical patent/OA13136A/en

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 857
230000002685 pulmonary effect Effects 0.000 title claims description 17
229940125396 insulin Drugs 0.000 claims abstract description 437
102000004877 Insulin Human genes 0.000 claims abstract description 407
108090001061 Insulin Proteins 0.000 claims abstract description 407
210000004072 lung Anatomy 0.000 claims abstract description 59
239000000203 mixture Substances 0.000 claims description 231
229920001223 polyethylene glycol Polymers 0.000 claims description 197
239000002202 Polyethylene glycol Substances 0.000 claims description 165
238000000034 method Methods 0.000 claims description 64
-1 polyethylene Polymers 0.000 claims description 34
239000000546 pharmaceutical excipient Substances 0.000 claims description 24
230000008878 coupling Effects 0.000 claims description 19
238000010168 coupling process Methods 0.000 claims description 19
238000005859 coupling reaction Methods 0.000 claims description 19
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 14
230000002035 prolonged effect Effects 0.000 claims description 13
229920001477 hydrophilic polymer Polymers 0.000 claims description 12
238000002347 injection Methods 0.000 claims description 12
239000007924 injection Substances 0.000 claims description 12
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
239000000178 monomer Substances 0.000 claims description 10
239000000539 dimer Substances 0.000 claims description 9
150000002148 esters Chemical class 0.000 claims description 9
230000002459 sustained effect Effects 0.000 claims description 8
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 7
239000004698 Polyethylene Substances 0.000 claims description 7
230000021615 conjugation Effects 0.000 claims description 7
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 7
229920000573 polyethylene Polymers 0.000 claims description 7
238000010521 absorption reaction Methods 0.000 claims description 6
150000004649 carbonic acid derivatives Chemical class 0.000 claims description 6
229940071648 metered dose inhaler Drugs 0.000 claims description 6
230000017531 blood circulation Effects 0.000 claims description 5
230000002163 immunogen Effects 0.000 claims description 5
239000007788 liquid Substances 0.000 claims description 5
150000001408 amides Chemical class 0.000 claims description 4
239000004471 Glycine Substances 0.000 claims description 3
125000003545 alkoxy group Chemical group 0.000 claims description 3
229940112141 dry powder inhaler Drugs 0.000 claims description 3
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 2
150000001875 compounds Chemical class 0.000 claims description 2
239000006199 nebulizer Substances 0.000 claims description 2
239000013638 trimer Substances 0.000 claims description 2
125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 3
229920001515 polyalkylene glycol Polymers 0.000 claims 3
125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims 2
230000003914 insulin secretion Effects 0.000 claims 2
235000008733 Citrus aurantifolia Nutrition 0.000 claims 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims 1
240000006909 Tilia x europaea Species 0.000 claims 1
235000011941 Tilia x europaea Nutrition 0.000 claims 1
238000006356 dehydrogenation reaction Methods 0.000 claims 1
230000008021 deposition Effects 0.000 claims 1
239000004571 lime Substances 0.000 claims 1
210000002966 serum Anatomy 0.000 claims 1
230000003285 pharmacodynamic effect Effects 0.000 abstract 1
108700002854 polyethylene glycol(B1)- insulin Proteins 0.000 description 176
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 64
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 64
239000008103 glucose Substances 0.000 description 64
239000000843 powder Substances 0.000 description 57
238000009472 formulation Methods 0.000 description 50
241001465754 Metazoa Species 0.000 description 48
239000008280 blood Substances 0.000 description 47
210000004369 blood Anatomy 0.000 description 47
229920000642 polymer Polymers 0.000 description 35
239000000243 solution Substances 0.000 description 31
241000700159 Rattus Species 0.000 description 29
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 21
101000976075 Homo sapiens Insulin Proteins 0.000 description 20
239000002245 particle Substances 0.000 description 19
235000001014 amino acid Nutrition 0.000 description 18
229940024606 amino acid Drugs 0.000 description 18
150000001413 amino acids Chemical class 0.000 description 18
230000000694 effects Effects 0.000 description 16
230000015572 biosynthetic process Effects 0.000 description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
238000003786 synthesis reaction Methods 0.000 description 13
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
238000001990 intravenous administration Methods 0.000 description 12
238000006243 chemical reaction Methods 0.000 description 11
238000001727 in vivo Methods 0.000 description 11
108090000765 processed proteins & peptides Proteins 0.000 description 11
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
230000006320 pegylation Effects 0.000 description 10
239000000047 product Substances 0.000 description 10
241000894007 species Species 0.000 description 10
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
239000003814 drug Substances 0.000 description 9
239000002953 phosphate buffered saline Substances 0.000 description 9
102000004196 processed proteins & peptides Human genes 0.000 description 9
230000009885 systemic effect Effects 0.000 description 9
229940079593 drug Drugs 0.000 description 8
239000004026 insulin derivative Substances 0.000 description 8
230000001629 suppression Effects 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
239000002253 acid Substances 0.000 description 7
239000000654 additive Substances 0.000 description 7
125000004429 atom Chemical group 0.000 description 7
230000000975 bioactive effect Effects 0.000 description 7
230000002829 reductive effect Effects 0.000 description 7
239000000126 substance Substances 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
239000004472 Lysine Substances 0.000 description 6
230000009471 action Effects 0.000 description 6
238000013459 approach Methods 0.000 description 6
230000000875 corresponding effect Effects 0.000 description 6
229940088598 enzyme Drugs 0.000 description 6
238000004128 high performance liquid chromatography Methods 0.000 description 6
239000008194 pharmaceutical composition Substances 0.000 description 6
239000007921 spray Substances 0.000 description 6
238000001694 spray drying Methods 0.000 description 6
239000011550 stock solution Substances 0.000 description 6
235000000346 sugar Nutrition 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
241001415846 Procellariidae Species 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
230000003213 activating effect Effects 0.000 description 5
125000003277 amino group Chemical group 0.000 description 5
238000007385 chemical modification Methods 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
239000006185 dispersion Substances 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
238000001035 drying Methods 0.000 description 5
125000005647 linker group Chemical group 0.000 description 5
125000006239 protecting group Chemical group 0.000 description 5
238000004007 reversed phase HPLC Methods 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
238000001542 size-exclusion chromatography Methods 0.000 description 5
150000008163 sugars Chemical class 0.000 description 5
238000012360 testing method Methods 0.000 description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
229910019142 PO4 Inorganic materials 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
235000014113 dietary fatty acids Nutrition 0.000 description 4
230000029087 digestion Effects 0.000 description 4
238000009826 distribution Methods 0.000 description 4
AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical class C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 4
239000003623 enhancer Substances 0.000 description 4
230000006862 enzymatic digestion Effects 0.000 description 4
230000002255 enzymatic effect Effects 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
229930195729 fatty acid Natural products 0.000 description 4
239000000194 fatty acid Substances 0.000 description 4
150000004665 fatty acids Chemical group 0.000 description 4
238000010304 firing Methods 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
230000035772 mutation Effects 0.000 description 4
239000010452 phosphate Substances 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
238000003127 radioimmunoassay Methods 0.000 description 4
230000004044 response Effects 0.000 description 4
239000000725 suspension Substances 0.000 description 4
230000001839 systemic circulation Effects 0.000 description 4
PBKONEOXTCPAFI-UHFFFAOYSA-N 1,2,4-trichlorobenzene Chemical compound ClC1=CC=C(Cl)C(Cl)=C1 PBKONEOXTCPAFI-UHFFFAOYSA-N 0.000 description 3
ASUGWWOMVNVWAW-UHFFFAOYSA-N 1-(2-methoxyethyl)pyrrole-2,5-dione Chemical compound COCCN1C(=O)C=CC1=O ASUGWWOMVNVWAW-UHFFFAOYSA-N 0.000 description 3
208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 description 3
102000009027 Albumins Human genes 0.000 description 3
108010088751 Albumins Proteins 0.000 description 3
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 3
229920000858 Cyclodextrin Polymers 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
108010092217 Long-Acting Insulin Proteins 0.000 description 3
102000016261 Long-Acting Insulin Human genes 0.000 description 3
229940100066 Long-acting insulin Drugs 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
150000001241 acetals Chemical class 0.000 description 3
235000012538 ammonium bicarbonate Nutrition 0.000 description 3
239000001099 ammonium carbonate Substances 0.000 description 3
230000036765 blood level Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
230000004087 circulation Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
235000018417 cysteine Nutrition 0.000 description 3
238000013461 design Methods 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
239000003480 eluent Substances 0.000 description 3
239000012634 fragment Substances 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
239000007789 gas Substances 0.000 description 3
238000003304 gavage Methods 0.000 description 3
230000010030 glucose lowering effect Effects 0.000 description 3
125000003827 glycol group Chemical group 0.000 description 3
230000007062 hydrolysis Effects 0.000 description 3
238000006460 hydrolysis reaction Methods 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
239000007972 injectable composition Substances 0.000 description 3
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
238000004949 mass spectrometry Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 3
238000002156 mixing Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
229940068196 placebo Drugs 0.000 description 3
239000000902 placebo Substances 0.000 description 3
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
238000012552 review Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
238000003860 storage Methods 0.000 description 3
238000010254 subcutaneous injection Methods 0.000 description 3
239000007929 subcutaneous injection Substances 0.000 description 3
125000003396 thiol group Chemical group [H]S* 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
239000003643 water by type Substances 0.000 description 3
ZJIFDEVVTPEXDL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) hydrogen carbonate Chemical compound OC(=O)ON1C(=O)CCC1=O ZJIFDEVVTPEXDL-UHFFFAOYSA-N 0.000 description 2
DHKHKXVYLBGOIT-UHFFFAOYSA-N 1,1-Diethoxyethane Chemical compound CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
108090000317 Chymotrypsin Proteins 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
229920001612 Hydroxyethyl starch Polymers 0.000 description 2
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
102000015731 Peptide Hormones Human genes 0.000 description 2
108010038988 Peptide Hormones Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000000149 argon plasma sintering Methods 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
229960002376 chymotrypsin Drugs 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
150000002118 epoxides Chemical class 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000010419 fine particle Substances 0.000 description 2
238000005189 flocculation Methods 0.000 description 2
230000016615 flocculation Effects 0.000 description 2
230000009477 glass transition Effects 0.000 description 2
125000001183 hydrocarbyl group Chemical group 0.000 description 2
DNZMDASEFMLYBU-RNBXVSKKSA-N hydroxyethyl starch Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O.OCCOC[C@H]1O[C@H](OCCO)[C@H](OCCO)[C@@H](OCCO)[C@@H]1OCCO DNZMDASEFMLYBU-RNBXVSKKSA-N 0.000 description 2
229940050526 hydroxyethylstarch Drugs 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
239000012535 impurity Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 2
229960002725 isoflurane Drugs 0.000 description 2
210000004731 jugular vein Anatomy 0.000 description 2
239000002502 liposome Substances 0.000 description 2
229920001427 mPEG Polymers 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
239000013081 microcrystal Substances 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 2
239000000813 peptide hormone Substances 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
230000004962 physiological condition Effects 0.000 description 2
229920001308 poly(aminoacid) Polymers 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000011148 porous material Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000011084 recovery Methods 0.000 description 2
238000007873 sieving Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
229960002317 succinimide Drugs 0.000 description 2
150000005846 sugar alcohols Chemical class 0.000 description 2
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
210000003437 trachea Anatomy 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
238000011282 treatment Methods 0.000 description 2
239000000811 xylitol Substances 0.000 description 2
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
235000010447 xylitol Nutrition 0.000 description 2
229960002675 xylitol Drugs 0.000 description 2
239000011701 zinc Substances 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 description 1
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
MLKLDGSYMHFAOC-AREMUKBSSA-N 1,2-dicapryl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCC MLKLDGSYMHFAOC-AREMUKBSSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
125000005917 3-methylpentyl group Chemical group 0.000 description 1
125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
QXZGLTYKKZKGLN-UHFFFAOYSA-N 4-(2,5-dioxopyrrolidin-1-yl)oxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)ON1C(=O)CCC1=O QXZGLTYKKZKGLN-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
239000004604 Blowing Agent Substances 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
235000005273 Canna coccinea Nutrition 0.000 description 1
240000008555 Canna flaccida Species 0.000 description 1
241001631457 Cannula Species 0.000 description 1
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
108010076119 Caseins Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical class OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
241001269524 Dura Species 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
XYZZKVRWGOWVGO-UHFFFAOYSA-N Glycerol-phosphate Chemical compound OP(O)(O)=O.OCC(O)CO XYZZKVRWGOWVGO-UHFFFAOYSA-N 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
238000011993 High Performance Size Exclusion Chromatography Methods 0.000 description 1
101000629400 Homo sapiens Mesoderm-specific transcript homolog protein Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010053317 Hydrophobia Diseases 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
101710186630 Insulin-1 Proteins 0.000 description 1
102100021496 Insulin-degrading enzyme Human genes 0.000 description 1
108090000828 Insulysin Proteins 0.000 description 1
108010081368 Isophane Insulin Proteins 0.000 description 1
102000005237 Isophane Insulin Human genes 0.000 description 1
LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229920002884 Laureth 4 Polymers 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229920002774 Maltodextrin Polymers 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102100026821 Mesoderm-specific transcript homolog protein Human genes 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
101150034459 Parpbp gene Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
241000009328 Perro Species 0.000 description 1
206010034912 Phobia Diseases 0.000 description 1
229920005372 Plexiglas® Polymers 0.000 description 1
108010020346 Polyglutamic Acid Proteins 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
108010076181 Proinsulin Proteins 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
229940123452 Rapid-acting insulin Drugs 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
108010026951 Short-Acting Insulin Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
241000950638 Symphysodon discus Species 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N THREONINE Chemical compound CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
108010036928 Thiorphan Proteins 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
108010061168 Ultralente Insulin Proteins 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000011256 aggressive treatment Methods 0.000 description 1
238000007605 air drying Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000002216 antistatic agent Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
238000000889 atomisation Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
150000003857 carboxamides Chemical class 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
150000001945 cysteines Chemical class 0.000 description 1
230000006240 deamidation Effects 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
229940096516 dextrates Drugs 0.000 description 1
239000008355 dextrose injection Substances 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
239000001177 diphosphate Substances 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
YNEZHFVWHPMBGA-UHFFFAOYSA-N ditert-butyl 2-(3-butoxycarbonyloxypropyl)propanedioate Chemical group CCCCOC(=O)OCCCC(C(=O)OC(C)(C)C)C(=O)OC(C)(C)C YNEZHFVWHPMBGA-UHFFFAOYSA-N 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000008393 encapsulating agent Substances 0.000 description 1
238000001976 enzyme digestion Methods 0.000 description 1
229950000206 estolate Drugs 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
PHTXVQQRWJXYPP-UHFFFAOYSA-N ethyltrifluoromethylaminoindane Chemical compound C1=C(C(F)(F)F)C=C2CC(NCC)CC2=C1 PHTXVQQRWJXYPP-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
150000002194 fatty esters Chemical class 0.000 description 1
210000003191 femoral vein Anatomy 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
229960001731 gluceptate Drugs 0.000 description 1
KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
239000000174 gluconic acid Chemical class 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
150000002303 glucose derivatives Polymers 0.000 description 1
150000002304 glucoses Polymers 0.000 description 1
125000002791 glucosyl group Polymers C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
238000000227 grinding Methods 0.000 description 1
ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
239000004030 hiv protease inhibitor Substances 0.000 description 1
229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
150000002466 imines Chemical class 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
108010033606 insulin dimers Proteins 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000012948 isocyanate Substances 0.000 description 1
150000002513 isocyanates Chemical class 0.000 description 1
HOQADATXFBOEGG-UHFFFAOYSA-N isofenphos Chemical compound CCOP(=S)(NC(C)C)OC1=CC=CC=C1C(=O)OC(C)C HOQADATXFBOEGG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
239000000832 lactitol Substances 0.000 description 1
VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
235000010448 lactitol Nutrition 0.000 description 1
229960003451 lactitol Drugs 0.000 description 1
JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical class OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229940062711 laureth-9 Drugs 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
229940049920 malate Drugs 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
229940127554 medical product Drugs 0.000 description 1
QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000011259 mixed solution Substances 0.000 description 1
239000003607 modifier Substances 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
239000002077 nanosphere Substances 0.000 description 1
238000002663 nebulization Methods 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000005457 optimization Methods 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
150000002905 orthoesters Chemical class 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
238000012510 peptide mapping method Methods 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
208000019899 phobic disease Diseases 0.000 description 1
150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
229940067605 phosphatidylethanolamines Drugs 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000765 poly(2-oxazolines) Polymers 0.000 description 1
229920002643 polyglutamic acid Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
230000000291 postprandial effect Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
229940048914 protamine Drugs 0.000 description 1
108010000947 protamine zinc Proteins 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
230000007017 scission Effects 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
238000007789 sealing Methods 0.000 description 1
238000004513 sizing Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 description 1
229910001488 sodium perchlorate Inorganic materials 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000003457 sulfones Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
239000006068 taste-masking agent Substances 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
LJJKNPQAGWVLDQ-SNVBAGLBSA-N thiorphan Chemical compound OC(=O)CNC(=O)[C@@H](CS)CC1=CC=CC=C1 LJJKNPQAGWVLDQ-SNVBAGLBSA-N 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229940073585 tromethamine hydrochloride Drugs 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
150000003673 urethanes Chemical class 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
239000004474 valine Substances 0.000 description 1
229940070384 ventolin Drugs 0.000 description 1
239000011800 void material Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Diabetes (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

OA1200300305A 2001-05-21 2002-05-21 Pulmonary administration of chemically modified insulin. OA13136A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US29242301P	2001-05-21	2001-05-21

Publications (1)

Publication Number	Publication Date
OA13136A true OA13136A (en)	2006-12-13

Family

ID=23124608

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200300305A OA13136A (en)	2001-05-21	2002-05-21	Pulmonary administration of chemically modified insulin.

Country Status (35)

Country	Link
US (3)	US6838076B2 (is)
EP (1)	EP1395294A4 (is)
JP (1)	JP2004535401A (is)
KR (1)	KR20030097876A (is)
CN (2)	CN1314445C (is)
AP (1)	AP1763A (is)
AR (1)	AR033903A1 (is)
AU (1)	AU2002303869B2 (is)
BG (1)	BG108494A (is)
BR (1)	BR0209896A (is)
CA (1)	CA2447236A1 (is)
CO (1)	CO5540371A2 (is)
CZ (1)	CZ20033182A3 (is)
EA (1)	EA007408B1 (is)
EC (1)	ECSP034855A (is)
GE (1)	GEP20063917B (is)
HR (1)	HRP20030949A2 (is)
HU (1)	HUP0400442A2 (is)
IL (2)	IL158862A0 (is)
IS (1)	IS7043A (is)
LT (1)	LT5153B (is)
LV (1)	LV13197B (is)
MA (1)	MA26185A1 (is)
MX (1)	MXPA03010649A (is)
MY (1)	MY137181A (is)
NO (1)	NO20035157D0 (is)
NZ (1)	NZ529572A (is)
OA (1)	OA13136A (is)
PL (1)	PL366911A1 (is)
SK (1)	SK15532003A3 (is)
TN (1)	TNSN03116A1 (is)
TR (1)	TR200400295T2 (is)
WO (1)	WO2002094200A2 (is)
YU (1)	YU98503A (is)
ZA (1)	ZA200309085B (is)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20060171899A1 (en) *	1998-12-10	2006-08-03	Akwete Adjei	Water-stabilized aerosol formulation system and method of making
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
JP2004535401A (ja) *	2001-05-21	2004-11-25	ネクターセラピューティックス	化学的に改変されたインスリンの肺投与
NZ519403A (en) *	2001-06-21	2005-03-24	Pfizer Prod Inc	Use of insulin in a medicament to reduce weight gain in a diabetic patient who is using exogenous insulin to control blood sugar levels
DE60231428D1 (de)	2001-12-21	2009-04-16	3M Innovative Properties Co	Medizinische aerosolzusammensetzungen mit einem funktionalisierten polyethylenglykol-hilfsstoff
US6923175B2 (en)	2002-03-20	2005-08-02	Mannkind Corporation	Inhalation apparatus
US7153829B2 (en)	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
WO2003103475A2 (en)	2002-06-07	2003-12-18	Dyax Corp.	Prevention and reduction of blood loss
WO2004075923A2 (en) *	2003-02-26	2004-09-10	Nektar Therapeutics Al, Corporation	Polymer-factor viii moiety conjugates
CA2521381C (en) *	2003-04-11	2020-05-26	Rezolute, Inc.	Method for preparation of site-specific protein conjugates
EP1491554A1 (en) *	2003-06-23	2004-12-29	CONARIS research institute AG	PEGylated soluble gp130-dimers useful as a medicament
WO2005021556A2 (en) *	2003-08-29	2005-03-10	Dyax Corp.	Modified protease inhibitors
PT1663281E (pt) *	2003-08-29	2014-03-17	Dyax Corp	Inibidores de proteases poli-peguilados
GB0328629D0 (en) *	2003-12-10	2004-01-14	Medpharm Ltd	Metered dose inhalation preparations
WO2005115477A2 (en)	2004-04-13	2005-12-08	Quintessence Biosciences, Inc.	Non-natural ribonuclease conjugates as cytotoxic agents
BRPI0513508B1 (pt) *	2004-07-19	2021-06-01	Biocon Limited	Conjugados de insulina-oligômero, formulações e usos desses
ATE486064T1 (de)	2004-08-20	2010-11-15	Mannkind Corp	Katalyse der diketopiperazinsynthese
KR20130066695A (ko)	2004-08-23	2013-06-20	맨카인드 코포레이션	약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
US20060046852A1 (en) *	2004-08-26	2006-03-02	Rowe Richard E	Wide area gaming system
US7235530B2 (en)	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US8245758B2 (en) *	2006-10-30	2012-08-21	GM Global Technology Operations LLC	Coulomb damped disc brake rotor and method of manufacturing
US20080206342A1 (en) *	2005-01-10	2008-08-28	Rosemary Kovelesky	Compositions and Methods For Increasing the Bioavailability of Pulmonarily Administered Insulin
EP1843790A2 (en) *	2005-01-27	2007-10-17	Novo Nordisk A/S	Insulin derivatives conjugated with structurally well defined branched polymers
TWI376234B (en) *	2005-02-01	2012-11-11	Msd Oss Bv	Conjugates of a polypeptide and an oligosaccharide
EP1846447B1 (en)	2005-02-02	2013-08-21	Novo Nordisk A/S	Insulin derivatives
WO2006082204A1 (en)	2005-02-02	2006-08-10	Novo Nordisk A/S	Insulin derivatives
EP1863840A1 (en) *	2005-03-18	2007-12-12	Novo Nordisk A/S	Pegylated single-chain insulin
US20060271011A1 (en) *	2005-05-25	2006-11-30	Mock Bradley D	Methods and apparatus for indicating when a disposable component of a drug delivery system needs to be replaced
MX373000B (es)	2005-09-14	2020-05-21	Mannkind Corp	Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
US8168592B2 (en) *	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
US20070174128A1 (en) *	2005-11-30	2007-07-26	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US20080004905A1 (en) *	2006-06-28	2008-01-03	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Methods and systems for analysis of nutraceutical associated components
US7927787B2 (en) *	2006-06-28	2011-04-19	The Invention Science Fund I, Llc	Methods and systems for analysis of nutraceutical associated components
US10296720B2 (en) *	2005-11-30	2019-05-21	Gearbox Llc	Computational systems and methods related to nutraceuticals
US20070289258A1 (en) *	2006-06-14	2007-12-20	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Individualized pharmaceutical selection and packaging
US20110145009A1 (en) *	2005-11-30	2011-06-16	Jung Edward K Y	Methods and systems related to transmission of nutraceutical associatd information
US8297028B2 (en)	2006-06-14	2012-10-30	The Invention Science Fund I, Llc	Individualized pharmaceutical selection and packaging
US7827042B2 (en) *	2005-11-30	2010-11-02	The Invention Science Fund I, Inc	Methods and systems related to transmission of nutraceutical associated information
US8340944B2 (en) *	2005-11-30	2012-12-25	The Invention Science Fund I, Llc	Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US20070124219A1 (en) *	2005-11-30	2007-05-31	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational and/or control systems related to individualized nutraceutical selection and packaging
US20080103746A1 (en) *	2005-11-30	2008-05-01	Searete Llc, A Limited Liability Corporation	Systems and methods for pathogen detection and response
US7974856B2 (en)	2005-11-30	2011-07-05	The Invention Science Fund I, Llc	Computational systems and methods related to nutraceuticals
US8000981B2 (en)	2005-11-30	2011-08-16	The Invention Science Fund I, Llc	Methods and systems related to receiving nutraceutical associated information
US20080114577A1 (en) *	2005-11-30	2008-05-15	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational methods and systems associated with nutraceutical related assays
US20070124176A1 (en) *	2005-11-30	2007-05-31	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US20080033763A1 (en) *	2005-11-30	2008-02-07	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Methods and systems related to receiving nutraceutical associated information
US20070136092A1 (en) *	2005-11-30	2007-06-14	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US20080052114A1 (en) *	2005-11-30	2008-02-28	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Computational systems and methods related to nutraceuticals
JP5738516B2 (ja)	2005-12-30	2015-06-24	ゼンサン（シャンハイ）サイエンスアンドテクノロジーリミテッド	心機能改善のためのニューレグリンの徐放
EP1986679B1 (en) *	2006-02-22	2017-10-25	MannKind Corporation	A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US20070292404A1 (en) *	2006-03-27	2007-12-20	Biosynexus Incorporated	Antimicrobial polymer conjugates
EP2044097A4 (en)	2006-06-23	2010-10-06	Quintessence Biosciences Inc	Modified ribonucleases
DK1873166T3 (da)	2006-06-30	2010-12-20	Conaris Res Inst Ag	Forbedrede sgp 130Fc-dimerer
US8298801B2 (en) *	2006-07-17	2012-10-30	Quintessence Biosciences, Inc.	Methods and compositions for the treatment of cancer
ES2542146T3 (es) *	2006-07-31	2015-07-31	Novo Nordisk A/S	Insulinas extendidas PEGiladas.
US20090208480A1 (en) *	2006-08-04	2009-08-20	Yue Huang	Long half-life recombinant butyrylcholinesterase
DK2074141T3 (en)	2006-09-22	2016-11-28	Novo Nordisk As	The protease resistant insulin analogues.
US8110655B2 (en)	2006-11-13	2012-02-07	Auxagen, Inc.	Method to promote hair growth and/or delay or treat hair loss by administering a TGF-β antagonist or inhibitor
WO2008084051A1 (en) *	2007-01-12	2008-07-17	Novo Nordisk A/S	Mixtures of pegylated insulin and fast acting insulin for pulmonary administration
US20140011964A1 (en)	2007-02-28	2014-01-09	Serina Therapeutics, Inc.	Activated Polyoxazolines and Conjugates and Compositions Comprising the Same
KR101508621B1 (ko) *	2007-02-28	2015-04-07	세리나 쎄라퓨틱스, 인코포레이티드	활성화된 폴리옥사졸린 및 이를 포함하는 조성물
US9387176B2 (en)	2007-04-30	2016-07-12	Novo Nordisk A/S	Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
US8633152B2 (en) *	2007-08-07	2014-01-21	Nanomaterials Technology Pte Ltd	Process for making micro-sized protein particles
EP2192904B1 (en) *	2007-08-27	2016-08-17	Auxagen, Inc.	METHODS FOR INHIBITING TGF-beta
EP2205271B1 (en) *	2007-10-08	2014-05-21	Quintessence Biosciences, Inc.	Compositions and methods for ribonuclease-based therapies
JP5868594B2 (ja)	2007-10-16	2016-02-24	バイオコン・リミテッドＢｉｏｃｏｎＬｉｍｉｔｅｄ	経口投与可能な固形医薬組成物及びそのプロセス
WO2009065126A2 (en) *	2007-11-16	2009-05-22	Boston Protein Solutions	Excipients for protein stabilization
WO2009112583A2 (en)	2008-03-14	2009-09-17	Novo Nordisk A/S	Protease-stabilized insulin analogues
CN102037008B (zh)	2008-03-18	2016-08-31	诺沃-诺迪斯克有限公司	蛋白酶稳定化的、酰化胰岛素类似物
US8488661B2 (en) *	2008-06-13	2013-07-16	Verizon Patent And Licensing Inc.	Systems and methods for data streaming
CN101827626B (zh)	2008-06-13	2015-03-18	曼金德公司	干粉吸入器和用于药物输送的系统
TWI451876B (zh) *	2008-06-13	2014-09-11	Lilly Co Eli	聚乙二醇化之離脯胰島素化合物
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
ES2421385T3 (es)	2008-06-20	2013-09-02	Mannkind Corp	Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI532497B (zh)	2008-08-11	2016-05-11	曼凱公司	超快起作用胰島素之用途
US8487006B2 (en) *	2008-09-16	2013-07-16	Auxagen, Inc.	Method of enhancing TGF-β signalling
EP2341942A1 (en)	2008-09-19	2011-07-13	Nektar Therapeutics	Polymer conjugates of therapeutic peptides
WO2010033220A2 (en) *	2008-09-19	2010-03-25	Nektar Therapeutics	Modified therapeutics peptides, methods of their preparation and use
US8029782B2 (en)	2008-10-01	2011-10-04	Quintessence Biosciences, Inc.	Therapeutic ribonucleases
EP2379511B1 (en)	2008-12-29	2014-12-17	MannKind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
CA2744235A1 (en)	2009-01-06	2010-07-15	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
DK2405963T3 (da)	2009-03-11	2013-12-16	Mannkind Corp	Apparat, system og fremgangsmåde til at måle modstand i en inhalator
KR102584844B1 (ko)	2009-06-12	2023-10-04	맨카인드 코포레이션	한정된 비표면적을 갖는 디케토피페라진 마이크로입자
AU2010277559B2 (en)	2009-07-31	2016-08-11	Sanofi-Aventis Deutschland Gmbh	Prodrugs comprising an insulin linker conjugate
PL2459171T3 (pl)	2009-07-31	2017-11-30	Sanofi-Aventis Deutschland Gmbh	Kompozycja insuliny o długim działaniu
CN102917699A (zh)	2009-10-13	2013-02-06	密执安大学评议会	树枝状聚合物组合物和合成方法
CA2778698A1 (en)	2009-11-03	2011-05-12	Mannkind Corporation	An apparatus and method for simulating inhalation efforts
JP2013526840A (ja)	2009-12-21	2013-06-27	ファーマシーネ，インコーポレイテッド	組み換えブチリルコリンエステラーゼおよびその切断型
EP3459564B1 (en)	2010-01-06	2021-10-27	Takeda Pharmaceutical Company Limited	Plasma kallikrein binding proteins
AR081066A1 (es) *	2010-04-02	2012-06-06	Hanmi Holdings Co Ltd	Conjugado de insulina donde se usa un fragmento de inmunoglobulina
US9981017B2 (en)	2010-04-02	2018-05-29	Hanmi Science Co., Ltd.	Insulin conjugate using an immunoglobulin fragment
CN102985125A (zh)	2010-06-21	2013-03-20	曼金德公司	干粉药物输送系统和方法
EP2438930A1 (en)	2010-09-17	2012-04-11	Sanofi-Aventis Deutschland GmbH	Prodrugs comprising an exendin linker conjugate
CA2823776A1 (en)	2011-01-06	2012-07-12	Dyax Corp.	Plasma kallikrein binding proteins
EP2686003A2 (en) *	2011-03-15	2014-01-22	Novo Nordisk A/S	Human insulin analogues and derivatives comprising cysteine substitutions
CN102675452B (zh) *	2011-03-17	2015-09-16	重庆富进生物医药有限公司	具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
SG194034A1 (en)	2011-04-01	2013-11-29	Mannkind Corp	Blister package for pharmaceutical cartridges
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
MX2014004983A (es)	2011-10-24	2014-09-22	Mannkid Corp	Metodos y composiciones para tratar dolor.
CN102504022A (zh) *	2011-11-30	2012-06-20	苏州元基生物技术有限公司	含有保护赖氨酸的胰岛素原及使用其制备胰岛素的方法
US9481721B2 (en)	2012-04-11	2016-11-01	Novo Nordisk A/S	Insulin formulations
US9457096B2 (en)	2012-07-06	2016-10-04	Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet)	Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
KR102264177B1 (ko)	2012-07-12	2021-06-11	맨카인드 코포레이션	건조 분말 약물 전달 시스템 및 방법
WO2014066856A1 (en)	2012-10-26	2014-05-01	Mannkind Corporation	Inhalable influenza vaccine compositions and methods
US9707276B2 (en)	2012-12-03	2017-07-18	Merck Sharp & Dohme Corp.	O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
EP3587404B1 (en)	2013-03-15	2022-07-13	MannKind Corporation	Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
MX375448B (es)	2013-07-18	2025-03-06	Mannkind Corp	Composiciones farmacéuticas en polvo seco estables al calor y métodos.
EP3030294B1 (en)	2013-08-05	2020-10-07	MannKind Corporation	Insufflation apparatus
CN105792851B (zh)	2013-09-13	2023-10-10	斯克利普斯研究所	修饰的治疗剂及其组合物
AU2014333979B2 (en)	2013-10-07	2018-02-15	Novo Nordisk A/S	Novel derivative of an insulin analogue
AU2014364589B2 (en)	2013-12-18	2020-02-27	The California Institute For Biomedical Research	Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
LT3226888T (lt)	2014-12-01	2021-05-25	Ferring B.V.	Selektyvaus il-6-trans-signalinio inhibitoriaus skyrimas
RS65665B1 (sr)	2014-12-01	2024-07-31	Ferring Bv	Selektivne kompozicije inhibitora il-6-trans-signalizacije
AU2016366557B2 (en)	2015-12-11	2024-01-25	Takeda Pharmaceutical Company Limited	Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
WO2017180708A1 (en) *	2016-04-12	2017-10-19	Cell and Molecular Tissue Engineering, LLC	Systems, methods and products for minimizing tissue reactions and tissue injury at an infusion site
US10918756B2 (en) *	2016-11-02	2021-02-16	Dow Global Technologies Llc	Solid non-aqueous gel air odorizer
TWI700091B (zh)	2016-12-16	2020-08-01	丹麥商諾佛儂迪克股份有限公司	含胰島素醫藥組成物
AU2020397917A1 (en)	2019-12-04	2022-06-23	The Scripps Research Institute	GLP2 receptor agonists and methods of use
US12528880B2 (en)	2020-01-13	2026-01-20	Takeda Pharmaceutical Company Limited	Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
MX2023014771A (es)	2021-06-09	2024-03-19	Scripps Research Inst	Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso.

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
DOP1982004086A (es)	1981-08-27	1988-03-22	Lilly Co Eli	Formula farmaceutica que comprende insulina humana y proinsulina humana
US4652548A (en)	1981-08-27	1987-03-24	Eli Lilly And Company	Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
US4654324A (en)	1981-08-27	1987-03-31	Eli Lilly And Company	Human proinsulin pharmaceutical formulations
US4839341A (en) *	1984-05-29	1989-06-13	Eli Lilly And Company	Stabilized insulin formulations
DE69026306T2 (de)	1989-05-27	1996-10-17	Seikagaku Kogyo Co Ltd	Verfahren für die Herstellung von Polyethylenglykolderivate und modifizierte Proteine.
US5342940A (en)	1989-05-27	1994-08-30	Sumitomo Pharmaceuticals Company, Limited	Polyethylene glycol derivatives, process for preparing the same
US5652214A (en) *	1989-06-05	1997-07-29	Cephalon, Inc.	Treating disorders by application of insulin-like growth factors and analogs
US5766897A (en) *	1990-06-21	1998-06-16	Incyte Pharmaceuticals, Inc.	Cysteine-pegylated proteins
JP3051145B2 (ja)	1990-08-28	2000-06-12	住友製薬株式会社	新規なポリエチレングリコール誘導体修飾ペプチド
US6565841B1 (en) *	1991-03-15	2003-05-20	Amgen, Inc.	Pulmonary administration of granulocyte colony stimulating factor
US6024090A (en) *	1993-01-29	2000-02-15	Aradigm Corporation	Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5359030A (en)	1993-05-10	1994-10-25	Protein Delivery, Inc.	Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en)	1993-05-10	1997-10-28	Protein Delivery, Inc.	Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5565215A (en)	1993-07-23	1996-10-15	Massachusettes Institute Of Technology	Biodegradable injectable particles for imaging
US5889153A (en)	1994-05-20	1999-03-30	Hisamitsu Pharmaceutical Co., Inc.	Protein or polypeptide, method for producing the same and intermediate compound therefor
US5730990A (en)	1994-06-24	1998-03-24	Enzon, Inc.	Non-antigenic amine derived polymers and polymer conjugates
US5874064A (en) *	1996-05-24	1999-02-23	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery
DE19628143A1 (de)	1996-07-12	1998-01-15	Basf Ag	Verfahren zur Herstellung einer wäßrigen Polymerisatdispersion
DE69800640T2 (de)	1997-01-29	2001-07-05	Polymasc Pharmaceuticals Plc, London	Pegylationsverfahren
CN1240718C (zh)	1997-10-24	2006-02-08	诺沃挪第克公司	人胰岛素衍生物的聚集体
US5985263A (en)	1997-12-19	1999-11-16	Enzon, Inc.	Substantially pure histidine-linked protein polymer conjugates
NZ509239A (en)	1998-07-27	2002-10-25	Emisphere Tech Inc	2-(4-(N-salicyloyl)aminophenyl)propionic acid useful as a carrier in compositions for delivering active agents
WO2000033866A1 (en) *	1998-12-04	2000-06-15	Provalis Uk Limited	Pharmaceutical compositions containing insulin
CA2358463A1 (en)	1999-01-08	2000-07-13	Virginia Commonwealth University	Polymeric delivery agents and delivery agent compounds
US6309633B1 (en)	1999-06-19	2001-10-30	Nobex Corporation	Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US7169889B1 (en) *	1999-06-19	2007-01-30	Biocon Limited	Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6323311B1 (en) *	1999-09-22	2001-11-27	University Of Utah Research Foundation	Synthesis of insulin derivatives
WO2001068141A2 (en)	2000-03-17	2001-09-20	Maxygen Aps	Dispersions of polypeptide conjugates
US20020168323A1 (en) *	2001-05-11	2002-11-14	Igor Gonda	Optimization of the molecular properties and formulation of proteins delivered by inhalation
JP2004535401A (ja) *	2001-05-21	2004-11-25	ネクターセラピューティックス	化学的に改変されたインスリンの肺投与
US6828297B2 (en)	2001-06-04	2004-12-07	Nobex Corporation	Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
ATE395042T1 (de) *	2001-08-16	2008-05-15	Baxter Int	Darreichungsformen welche mikropartikel und treibgas enthalten

2002
- 2002-05-21 JP JP2002590921A patent/JP2004535401A/ja active Pending
- 2002-05-21 MY MYPI20021867A patent/MY137181A/en unknown
- 2002-05-21 CN CNB028103556A patent/CN1314445C/zh not_active Expired - Fee Related
- 2002-05-21 IL IL15886202A patent/IL158862A0/xx unknown
- 2002-05-21 CN CNA2007100855527A patent/CN101045166A/zh active Pending
- 2002-05-21 HU HU0400442A patent/HUP0400442A2/hu unknown
- 2002-05-21 AP APAP/P/2003/002918A patent/AP1763A/en active
- 2002-05-21 CA CA002447236A patent/CA2447236A1/en not_active Abandoned
- 2002-05-21 US US10/154,057 patent/US6838076B2/en not_active Expired - Lifetime
- 2002-05-21 AU AU2002303869A patent/AU2002303869B2/en not_active Ceased
- 2002-05-21 AR ARP020101877A patent/AR033903A1/es not_active Application Discontinuation
- 2002-05-21 TR TR2004/00295T patent/TR200400295T2/xx unknown
- 2002-05-21 YU YU98503A patent/YU98503A/sh unknown
- 2002-05-21 KR KR10-2003-7014954A patent/KR20030097876A/ko not_active Ceased
- 2002-05-21 HR HR20030949A patent/HRP20030949A2/xx not_active Application Discontinuation
- 2002-05-21 BR BR0209896-2A patent/BR0209896A/pt not_active Application Discontinuation
- 2002-05-21 WO PCT/US2002/016464 patent/WO2002094200A2/en not_active Ceased
- 2002-05-21 CZ CZ20033182A patent/CZ20033182A3/cs unknown
- 2002-05-21 EA EA200301222A patent/EA007408B1/ru not_active IP Right Cessation
- 2002-05-21 PL PL02366911A patent/PL366911A1/xx not_active Application Discontinuation
- 2002-05-21 SK SK1553-2003A patent/SK15532003A3/sk not_active Application Discontinuation
- 2002-05-21 GE GE5398A patent/GEP20063917B/en unknown
- 2002-05-21 MX MXPA03010649A patent/MXPA03010649A/es active IP Right Grant
- 2002-05-21 NZ NZ529572A patent/NZ529572A/en unknown
- 2002-05-21 OA OA1200300305A patent/OA13136A/en unknown
- 2002-05-21 EP EP02731931A patent/EP1395294A4/en not_active Withdrawn
2003
- 2003-04-01 US US10/405,190 patent/US6890518B2/en not_active Expired - Fee Related
- 2003-07-08 TN TNPCT/US2002/016464A patent/TNSN03116A1/en unknown
- 2003-11-13 IL IL158862A patent/IL158862A/en not_active IP Right Cessation
- 2003-11-19 IS IS7043A patent/IS7043A/is unknown
- 2003-11-20 CO CO03102566A patent/CO5540371A2/es unknown
- 2003-11-20 EC EC2003004855A patent/ECSP034855A/es unknown
- 2003-11-20 NO NO20035157A patent/NO20035157D0/no unknown
- 2003-11-21 LV LVP-03-131A patent/LV13197B/en unknown
- 2003-11-21 MA MA27413A patent/MA26185A1/fr unknown
- 2003-12-17 LT LT2003107A patent/LT5153B/lt not_active IP Right Cessation
- 2003-12-22 BG BG108494A patent/BG108494A/xx unknown
2004
- 2004-11-02 US US10/980,652 patent/US20050152848A1/en not_active Abandoned
- 2004-11-21 ZA ZA200309085A patent/ZA200309085B/en unknown

Also Published As

Publication number	Publication date
MY137181A (en)	2009-01-30
EP1395294A2 (en)	2004-03-10
LT5153B (lt)	2004-08-25
EP1395294A4 (en)	2006-01-11
CO5540371A2 (es)	2005-07-29
WO2002094200A3 (en)	2003-02-20
US6890518B2 (en)	2005-05-10
CA2447236A1 (en)	2002-11-28
BR0209896A (pt)	2004-08-17
EA200301222A1 (ru)	2004-08-26
WO2002094200A2 (en)	2002-11-28
US6838076B2 (en)	2005-01-04
AU2002303869B2 (en)	2007-08-16
MXPA03010649A (es)	2005-10-05
HRP20030949A2 (en)	2005-04-30
KR20030097876A (ko)	2003-12-31
SK15532003A3 (sk)	2004-06-08
JP2004535401A (ja)	2004-11-25
CN1582171A (zh)	2005-02-16
TNSN03116A1 (en)	2005-12-23
AP2003002918A0 (en)	2003-12-31
ZA200309085B (en)	2004-11-22
CN101045166A (zh)	2007-10-03
US20030118510A1 (en)	2003-06-26
CZ20033182A3 (cs)	2004-09-15
LV13197B (en)	2004-10-20
PL366911A1 (en)	2005-02-07
NO20035157D0 (no)	2003-11-20
IL158862A0 (en)	2004-05-12
CN1314445C (zh)	2007-05-09
MA26185A1 (fr)	2004-07-01
IL158862A (en)	2008-07-08
TR200400295T2 (tr)	2005-04-21
HUP0400442A2 (hu)	2005-03-29
US20030216542A1 (en)	2003-11-20
YU98503A (sh)	2006-05-25
AP1763A (en)	2007-08-02
US20050152848A1 (en)	2005-07-14
ECSP034855A (es)	2004-03-23
GEP20063917B (en)	2006-09-11
NZ529572A (en)	2006-02-24
IS7043A (is)	2003-11-19
BG108494A (en)	2004-07-30
LT2003107A (en)	2004-05-25
AR033903A1 (es)	2004-01-07
EA007408B1 (ru)	2006-10-27

Publication	Publication Date	Title
OA13136A (en)	2006-12-13	Pulmonary administration of chemically modified insulin.
AU2002303869A1 (en)	2003-05-08	Pulmonary administration of chemically modified insulin
EP2049149B1 (en)	2015-04-15	Pegylated extended insulins
JP5721432B2 (ja)	2015-05-20	アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
JP5688969B2 (ja)	2015-03-25	プロテアーゼに対して安定しているペグ化インスリンアナログ
EP2364735A2 (en)	2011-09-14	Branched PEG conjugates of GLP-1
WO2010033220A2 (en)	2010-03-25	Modified therapeutics peptides, methods of their preparation and use
EP2017288A1 (en)	2009-01-21	Protease stabilized, pegylated insulin analogues
US20250134960A1 (en)	2025-05-01	Formulations for bovine granulocyte colony stimulating factor and variants thereof
US20080159964A1 (en)	2008-07-03	Use of adenosine deaminase for treating pulmonary disease
HK1171654A (en)	2013-04-05	Long acting insulin composition
HK1171654B (en)	2018-04-27	Long acting insulin composition